Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

7.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.0K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

854
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
854

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.

European journal of preventive cardiology·2026
Same author

Lipid-related cardiovascular risk beyond low-density lipoprotein cholesterol.

Heart (British Cardiac Society)·2026
Same author

Cardiovascular drug development: role of Mendelian randomization.

European heart journal·2026
Same author

Lifestyle characteristics and plasma biomarkers for risk of MASLD differ by sex in the general population.

European journal of internal medicine·2026
Same author

Feasibility of remnant cholesterol as a therapeutic target for atherosclerotic cardio-vascular disease.

Expert opinion on therapeutic targets·2026
Same author

VLDL cholesterol and ASCVD risk: A population-based study.

Journal of clinical lipidology·2026

Related Experiment Video

Updated: May 3, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K

Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study.

Mette Thomsen1, Anette Varbo, Anne Tybjærg-Hansen

  • 1Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark;

Clinical Chemistry
|January 18, 2014
PubMed
Summary

Lifelong lower nonfasting triglycerides, genetically determined, significantly reduce all-cause mortality risk. This suggests targeting triglyceride levels may prevent premature death.

Related Experiment Videos

Last Updated: May 3, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K

Area of Science:

  • Cardiovascular Disease Epidemiology
  • Genetic Epidemiology
  • Lipid Metabolism

Background:

  • Elevated nonfasting plasma triglycerides indicate increased remnant lipoprotein cholesterol, a cardiovascular disease risk factor.
  • The impact of genetically determined lifelong low triglyceride levels on all-cause mortality remains unclear.

Purpose of the Study:

  • To investigate whether genetically reduced nonfasting triglyceride concentrations are associated with reduced all-cause mortality.
  • To explore the role of lipoprotein lipase gene variants in modulating triglyceride levels and mortality risk.

Main Methods:

  • Mendelian randomization design utilizing data from the Copenhagen City Heart Study.
  • Observational analyses (n=13,957) assessed the association between nonfasting triglyceride levels and all-cause mortality.
  • Genetic analyses (n=10,208) examined the impact of lipoprotein lipase variants on triglyceride levels and mortality.

Main Results:

  • Observational analyses showed a dose-response reduction in all-cause mortality with lower nonfasting triglyceride concentrations.
  • Genetically lower nonfasting triglycerides (e.g., 1-mmol/L reduction) were associated with significantly reduced all-cause mortality (OR 0.50).
  • A 50% genetically derived reduction in nonfasting triglycerides corresponded to a 57% reduction in all-cause mortality (OR 0.43).

Conclusions:

  • Genetically determined lower nonfasting plasma triglyceride concentrations are linked to reduced all-cause mortality.
  • This association is likely mediated by decreased levels of cholesterol within remnant lipoproteins.
  • Findings support the hypothesis that lifelong triglyceride reduction confers survival benefits.